Table 3.
The regorafenib concentrations studied ranged from 0 to 20 μM concurrent with or following radiotherapy (RT) with sham RT (RT0 Gy), 2 Gy (RT2 Gy) and 9 Gy (RT9 Gy), and the estimated concentration at which 50% of cells were killed (IC50) for Huh-7 and Hep G2.
| Regorafenib (μM) | RT0 Gy | RT2 Gy | RT9 Gy | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C | S | C | S | C | S | |||||||
| Huh-7 | Hep G2 | Huh-7 | Hep G2 | Huh-7 | Hep G2 | Huh-7 | Hep G2 | Huh-7 | Hep G2 | Huh-7 | Hep G2 | |
| IC50 | 6.56 | 9.87 | 12.8 | 17.68 | 6.38 | 10.5 | 12.07 | 18.89 | 6.36 | 8.43 | 15.23 | 16.81 |
| 0 | 100.0 ± 0.0, | 100.0 ± 0.0 | 100.0 ± 0.0 | 100.0 ± 0.0 | 100.1 ± 6.0 | 94.0 ± 16.2 | 87.0 ± 3.3 | 84.3 ± 2.2 | 103.9 ± 27.4 | 98.9 ± 20.8 | 85.7 ± 6.9 | 86.9 ± 6.9 |
| 5 | 60.9 ± 1.8 | 74.6 ± 2.4 | 72.6 ± 1.0 | 82.0 ± 1.9 | 59.8 ± 5.5 | 73.1 ± 11.7 | 59.5 ± 2.7 | 72.1 ± 1.7 | 62.3 ± 14.1 | 64.7 ± 11.3 | 60.2 ± 5.6 | 71.0 ± 5.3 |
| 10 | 35.1 ± 1.6 | 51.3 ± 3.1 | 55.2 ± 1.2 | 67.0 ± 1.3 | 33.9 ± 2.7 | 50.8 ± 7.0 | 46.0 ± 2.9 | 64.1 ± 1.3 | 34.3 ± 5.3 | 46.7 ± 8.9 | 47.6 ± 3.0 | 64.2 ± 4.3 |
| 20 | 15.4 ± 1.0 | 24.7 ± 1.2 | 41.4 ± 0.4 | 46.0 ± 3.4 | 14.4 ± 0.8 | 24.5 ± 2.5 | 36.3 ± 1.4 | 42.4 ± 0.8 | 14.1 ± 0.7 | 20.6 ± 1.5 | 41.1 ± 1.7 | 38.5 ± 1.9 |
C: concurrent group, regorafenib was added to the plates 1 h following RT. S: sequential group, regorafenib was added to the plates 24 h following RT.